tbuckley/cabot-search huggingface dataset:
A Conversation with James Ntambi
Authors: James M. Ntambi, Patrick J. Stover
Journal: Annual Review of Nutrition (2023)

An interview with James M. Ntambi, professor of biochemistry and the Katherine Berns Van Donk Steenbock Professor in Nutrition, College of Agricultural and Life Sciences, at the University of Wisconsin-Madison, took place via Zoom in April 2022. He was interviewed by Patrick J. Stover, director of the Institute for Advancing Health through Agriculture and professor of nutrition and biochemistry and biophysics at Texas A&M University. Dr. James Ntambi is a true pioneer in the field of nutritional biochemistry. He was among the very first to discover and elucidate the role that diet and nutrients play in regulating metabolism through changes in the expression of metabolic genes, focusing on the de novo lipogenesis pathways. As an African immigrant from Uganda, his love of science and his life experiences in African communities suffering from severe malnutrition molded his scientific interests at the interface of biochemistry and nutrition. Throughout his career, he has been an academic role model, a groundbreaking nutrition scientist, and an educator. His commitment to experiential learning through the many study-abroad classes he has hosted in Uganda has provided invaluable context for American students in nutrition. Dr. Ntambi's passion for education and scientific discovery is his legacy, and the field of nutrition has benefited enormously from his unique perspectives and contributions to science that are defined by his scientific curiosity, his generosity to his students and colleagues, and his life experiences. The following is an edited transcript.
Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
Authors: I. Vaxman, S. K. Kumar, F. Buadi, M. Q. Lacy, D. Dingli, S. Hayman, T. Kourelis, R. Warsame, Y. Hwa, A. Fonder, M. Hobbs, E. Muchtar, N. Leung, P. Kapoor, R. Go, Y. Lin, W. Gonsalves, M. Siddiqui, R. A. Kyle, S. V. Rajkumar, M. A. Gertz, A. Dispenzieri
Journal: Blood Cancer Journal (2023)
Standard Restrictions vs Expedited Activity After Pelvic Organ Prolapse Surgery
Authors: Michele O’Shea, Nazema Y. Siddiqui, Tracy Truong, Alaattin Erkanli, Matthew D. Barber
Journal: JAMA Surgery (2023)

Restrictions on postoperative activity following pelvic organ prolapse (POP) surgery are not evidence based. Nonetheless, many pelvic surgeons place lifting and activity restrictions on patients following surgery.
Evaluation and Management of Deficiency of Adenosine Deaminase 2
Authors: Pui Y. Lee, Brad A. Davidson, Roshini S. Abraham, Blanche Alter, Juan I. Arostegui, Katherine Bell, Alexandre Belot, Jenna R. E. Bergerson, Timothy J. Bernard, Paul A. Brogan, Yackov Berkun, Natalie T. Deuitch, Dimana Dimitrova, Sophie A. Georgin-Lavialle, Marco Gattorno, Bodo Grimbacher, Hasan Hashem, Michael S. Hershfield, Rebecca N. Ichord, Kazushi Izawa, Jennifer A. Kanakry, Raju P. Khubchandani, Femke C.C. Klouwer, Evan A. Luton, Ada W. Man, Isabelle Meyts, Joris M. Van Montfrans, Seza Ozen, Janna Saarela, Gustavo C. Santo, Aman Sharma, Ariane Soldatos, Rachel Sparks, Troy R. Torgerson, Ignacio Leandro Uriarte, Taryn A. B. Youngstein, Qing Zhou, Ivona Aksentijevich, Daniel L. Kastner, Eugene P. Chambers, Amanda K. Ombrello, Mary K. Makley, Kristen L. Hayner, Bridget E. Kling, Lex M. Cowsert, Julie S. Williams
Journal: JAMA Network Open (2023)

Importance Deficiency of adenosine deaminase 2 (DADA2) is a recessively inherited disease characterized by systemic vasculitis, early-onset stroke, bone marrow failure, and/or immunodeficiency affecting both children and adults. DADA2 is among the more common monogenic autoinflammatory diseases, with an estimate of more than 35 000 cases worldwide, but currently, there are no guidelines for diagnostic evaluation or management. Objective To review the available evidence and develop multidisciplinary consensus statements for the evaluation and management of DADA2. Evidence Review The DADA2 Consensus Committee developed research questions based on data collected from the International Meetings on DADA2 organized by the DADA2 Foundation in 2016, 2018, and 2020. A comprehensive literature review was performed for articles published prior to 2022. Thirty-two consensus statements were generated using a modified Delphi process, and evidence was graded using the Oxford Center for Evidence-Based Medicine Levels of Evidence. Findings The DADA2 Consensus Committee, comprising 3 patient representatives and 35 international experts from 18 countries, developed consensus statements for (1) diagnostic testing, (2) screening, (3) clinical and laboratory evaluation, and (4) management of DADA2 based on disease phenotype. Additional consensus statements related to the evaluation and treatment of individuals with DADA2 who are presymptomatic and carriers were generated. Areas with insufficient evidence were identified, and questions for future research were outlined. Conclusions and Relevance DADA2 is a potentially fatal disease that requires early diagnosis and treatment. By summarizing key evidence and expert opinions, these consensus statements provide a framework to facilitate diagnostic evaluation and management of DADA2.
Finding a Quorum in Deficiency of Adenosine Deaminase 2 Management
Authors: Paul Tsoukas, Ronald M. Laxer
Journal: JAMA Network Open (2023)

Pui Y. Lee, MD, PhD; Brad A. Davidson, BS; Roshini S. Abraham, PhD; Blanche Alter, MD, MPH; Juan I. Arostegui, MD, PhD; Katherine Bell, MFA; Alexandre Belot, MD, PhD; Jenna R. E. Bergerson, MD, MPH; Timothy J. Bernard, MD, MSCS; Paul A. Brogan, BSc, MBChB, MSc, PhD; Yackov Berkun, MD; Natalie T. Deuitch, MS, CGC; Dimana Dimitrova, MD; Sophie A. Georgin-Lavialle, MD, PhD; Marco Gattorno, MD; Bodo Grimbacher, MD; Hasan Hashem, MD; Michael S. Hershfield, MD; Rebecca N. Ichord, MD; Kazushi Izawa, MD, PhD; Jennifer A. Kanakry, MD; Raju P. Khubchandani, MD; Femke C.C. Klouwer, MD, PhD; Evan A. Luton, MAT; Ada W. Man, MD; Isabelle Meyts, MD, PhD; Joris M. Van Montfrans, MD, PhD; Seza Ozen, MD; Janna Saarela, MD, PhD; Gustavo C. Santo, MD; Aman Sharma, MD; Ariane Soldatos, MD, MPH; Rachel Sparks, MD; Troy R. Torgerson, MD, PhD; Ignacio Leandro Uriarte, MD; Taryn A. B. Youngstein, MB, BS, MD; Qing Zhou, PhD; Ivona Aksentijevich, MD; Daniel L. Kastner, MD, PhD; Eugene P. Chambers, MD; Amanda K. Ombrello, MD; DADA2 Foundation; Mary K. Makley; Kristen L. Hayner; Bridget E. Kling; Lex M. Cowsert; Julie S. Williams
Humidity’s Role in Heat-Related Health Outcomes: A Heated Debate
Authors: Jane W. Baldwin, Tarik Benmarhnia, Kristie L. Ebi, Ollie Jay, Nicholas J. Lutsko, Jennifer K. Vanos
Journal: Environmental Health Perspectives (2023)

As atmospheric greenhouse gas concentrations continue to rise, temperature and humidity will increase further, causing potentially dire increases in human heat stress. On physiological and biophysical grounds, exposure to higher levels of humidity should worsen heat stress by decreasing sweat evaporation. However, population-scale epidemiological studies of heat exposure and response often do not detect associations between high levels of humidity and heat-related mortality or morbidity. These divergent, disciplinary views regarding the role of humidity in heat-related health risks limit confidence in selecting which interventions are effective in reducing health impacts and in projecting future heat-related health risks.
Oral Semaglutide Led to Similar Weight Loss as Injection, Company Says
Authors: Emily Harris
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genomic and epigenomic determinants of heat stress-induced transcriptional memory in Arabidopsis
Authors: Christian Kappel, Thomas Friedrich, Vicky Oberkofler, Li Jiang, Tim Crawford, Michael Lenhard, Isabel Bäurle
Journal: Genome biology (2023)

Abstract Background Transcriptional regulation is a key aspect of environmental stress responses. Heat stress induces transcriptional memory, i.e., sustained induction or enhanced re-induction of transcription, that allows plants to respond more efficiently to a recurrent HS. In light of more frequent temperature extremes due to climate change, improving heat tolerance in crop plants is an important breeding goal. However, not all heat stress-inducible genes show transcriptional memory, and it is unclear what distinguishes memory from non-memory genes. To address this issue and understand the genome and epigenome architecture of transcriptional memory after heat stress, we identify the global target genes of two key memory heat shock transcription factors, HSFA2 and HSFA3, using time course ChIP-seq. Results HSFA2 and HSFA3 show near identical binding patterns. In vitro and in vivo binding strength is highly correlated, indicating the importance of DNA sequence elements. In particular, genes with transcriptional memory are strongly enriched for a tripartite heat shock element, and are hallmarked by several features: low expression levels in the absence of heat stress, accessible chromatin environment, and heat stress-induced enrichment of H3K4 trimethylation. These results are confirmed by an orthogonal transcriptomic data set using both de novo clustering and an established definition of memory genes. Conclusions Our findings provide an integrated view of HSF-dependent transcriptional memory and shed light on its sequence and chromatin determinants, enabling the prediction and engineering of genes with transcriptional memory behavior.
Peptide Hydrogels as Immunomaterials and Their Use in Cancer Immunotherapy Delivery
Authors: Natashya Falcone, Menekse Ermis, Dilara Goksu Tamay, Marvin Mecwan, Mahsa Monirizad, Tess Grett Mathes, Vadim Jucaud, Auveen Choroomi, Natan Roberto de Barros, Yangzhi Zhu, Nihal Engin Vrana, Heinz‐Bernhard Kraatz, Han‐Jun Kim, Ali Khademhosseini
Journal: Advanced Healthcare Materials (2023)

Abstract Peptide‐based hydrogel biomaterials have emerged as an excellent strategy for immune system modulation. Peptide‐based hydrogels are supramolecular materials that self‐assemble into various nanostructures through various interactive forces (i.e., hydrogen bonding and hydrophobic interactions) and respond to microenvironmental stimuli (i.e., pH, temperature). While they have been reported in numerous biomedical applications, they have recently been deemed promising candidates to improve the efficacy of cancer immunotherapies and treatments. Immunotherapies seek to harness the body's immune system to preemptively protect against and treat various diseases, such as cancer. However, their low efficacy rates result in limited patient responses to treatment. Here, the immunomaterial's potential to improve these efficacy rates by either functioning as immune stimulators through direct immune system interactions and/or delivering a range of immune agents is highlighted. The chemical and physical properties of these peptide‐based materials that lead to immuno modulation and how one may design a system to achieve desired immune responses in a controllable manner are discussed. Works in the literature that reports peptide hydrogels as adjuvant systems and for the delivery of immunotherapies are highlighted. Finally, the future trends and possible developments based on peptide hydrogels for cancer immunotherapy applications are discussed.
Risk of Venous Thromboembolism Among Adults With Atopic Dermatitis
Authors: Tai-Li Chen, Wan-Ting Huang, Ching-Hui Loh, Huei-Kai Huang, Ching-Chi Chi
Journal: JAMA Dermatology (2023)

The associations of atopic dermatitis (AD) with multiple cardiovascular comorbidities have been investigated because of its pathomechanisms regarding chronic systemic inflammation and potential vascular effects. Nevertheless, the association between AD and incident venous thromboembolism (VTE) in adulthood is largely unknown. This study aimed to investigate the association of AD with incident VTE.
Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort
Authors: Hongyi Zhu, Lenian Zhou, Qiuke Wang, Qianying Cai, Fan Yang, Hanqiang Jin, Yiwei Chen, Yanyan Song, Changqing Zhang
Journal: Annals of the Rheumatic Diseases (2023)

Obesity is a risk factor for knee osteoarthritis (KOA) development and progression. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are indicated for type 2 diabetes mellitus (T2DM) and obesity. However, whether KOA patients can benefit from GLP-1RA therapies has not been sufficiently investigated, especially in the long term.The Shanghai Osteoarthritis Cohort study is a prospective, observational, multicentre study of >40 000 adults with clinically diagnosed osteoarthritis aged >45 years in Shanghai. We identified all KOA participants with comorbid T2DM enrolled from 1 January 2011 to 1 January 2017. Primary outcome was incidence of knee surgery after enrolment. Secondary outcomes included pain-relieving medication use, number of intra-articular therapies, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and medial femorotibial joint cartilage thickness. To evaluate the effects of GLP-1RA, we performed before-and-after comparison and comparison with participants who had no GLP-1RA exposure.For an intergroup comparison (non-GLP-1RA vs GLP-1RA), more weight loss (adjusted mean difference in weight change from baseline -7.29 kg (95% CI -8.07 to -6.50 kg), p<0.001) and lower incidence of knee surgery (93/1574 (5.9%) vs 4/233 (1.7%), adjusted p=0.014) were observed in the GLP-1RA group. Statistically significant differences in mean change from baseline for the WOMAC total and pain subscale scores were observed (adjusted mean difference in WOMAC total score -1.46 (95% CI -2.84 to -0.08), p=0.038; adjusted mean difference in WOMAC pain subscore -3.37 (95% CI -5.79 to -0.94), p=0.007). Cartilage-loss velocity of the medial femorotibial joint was significantly lower in the GLP-1RA group postadjustment for baseline characteristics (adjusted mean difference -0.02 mm (95% CI -0.03 to -0.002 mm), p=0.004). For the before-and-after comparison within the GLP-1RA group, we observed a significant decrease of symptom-relieving medication consumption and cartilage loss velocity of medial femorotibial joint (after-treatment vs before-treatment: -0.03±0.05 vs -0.05±0.07 mm/year, p<0.001). The association between GLP-1RA exposure and decreased incidence of knee surgery was mediated by weight reduction (mediation proportion: 32.1%), instead of glycaemic control (too small to calculate).With sufficient treatment duration, GLP-1RA therapies might be disease-modifying for KOA patients with comorbid T2DM, possibly mediated by weight loss. Further investigation is needed to elucidate effects of GLP-1RA on disease process, joint structure and patient-reported outcomes of osteoarthritis.
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
Authors: Karim Fizazi, Ken Herrmann, Bernd J Krause, Kambiz Rahbar, Kim N Chi, Michael J Morris, Oliver Sartor, Scott T Tagawa, Ayse T Kendi, Nicholas Vogelzang, Jeremie Calais, James Nagarajah, Xiao X Wei, Vadim S Koshkin, Jean-Mathieu Beauregard, Brian Chang, Ray Ghouse, Michelle DeSilvio, Richard A Messmann, Johann de Bono
Journal: The Lancet Oncology (2023)
The prognosis of patients with small cell carcinoma of the cervix: a retrospective study of the SEER database and a Chinese multicentre registry
Authors: Tian Chu, Yifan Meng, Ping Wu, Zheng Li, Hao Wen, Fang Ren, Dongling Zou, Huaiwu Lu, Lingying Wu, Shengtao Zhou, Ying Chen, Jundong Li, Miaochun Xu, Xiaoliu Wu, Xi Xiong, Zhibin Wang, Misi He, Yuanyuan Zhang, Shitong Lin, Canhui Cao, Wencheng Ding, Yu Chen, Wenhua Zhi, Ting Peng, Ye Wei, Binghan Liu, Yashi Xu, Ding Ma, Jing Wang, Chaoyang Sun, Peng Wu
Journal: The Lancet Oncology (2023)
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
Authors: Heinz Ludwig, Evangelos Terpos, Niels van de Donk, Maria-Victoria Mateos, Philippe Moreau, Melitios-Athanasios Dimopoulos, Michel Delforge, Paula Rodriguez-Otero, Jesús San-Miguel, Kwee Yong, Francesca Gay, Hermann Einsele, Roberto Mina, Jo Caers, Christoph Driessen, Pellegrino Musto, Sonja Zweegman, Monika Engelhardt, Gordon Cook, Katja Weisel, Annemiek Broijl, Meral Beksac, Jelena Bila, Fredrik Schjesvold, Michele Cavo, Roman Hajek, Cyrille Touzeau, Mario Boccadoro, Pieter Sonneveld
Journal: The Lancet Oncology (2023)
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study
Authors: Maliazurina B Saad, Lingzhi Hong, Muhammad Aminu, Natalie I Vokes, Pingjun Chen, Morteza Salehjahromi, Kang Qin, Sheeba J Sujit, Xuetao Lu, Elliana Young, Qasem Al-Tashi, Rizwan Qureshi, Carol C Wu, Brett W Carter, Steven H Lin, Percy P Lee, Saumil Gandhi, Joe Y Chang, Ruijiang Li, Michael F Gensheimer, Heather A Wakelee, Joel W Neal, Hyun-Sung Lee, Chao Cheng, Vamsidhar Velcheti, Yanyan Lou, Milena Petranovic, Waree Rinsurongkawong, Xiuning Le, Vadeerat Rinsurongkawong, Amy Spelman, Yasir Y Elamin, Marcelo V Negrao, Ferdinandos Skoulidis, Carl M Gay, Tina Cascone, Mara B Antonoff, Boris Sepesi, Jeff Lewis, Ignacio I Wistuba, John D Hazle, Caroline Chung, David Jaffray, Don L Gibbons, Ara Vaporciyan, J Jack Lee, John V Heymach, Jianjun Zhang, Jia Wu
Journal: The Lancet Digital Health (2023)

Only around 20-30% of patients with non-small-cell lung cancer (NCSLC) have durable benefit from immune-checkpoint inhibitors. Although tissue-based biomarkers (eg, PD-L1) are limited by suboptimal performance, tissue availability, and tumour heterogeneity, radiographic images might holistically capture the underlying cancer biology. We aimed to investigate the application of deep learning on chest CT scans to derive an imaging signature of response to immune checkpoint inhibitors and evaluate its added value in the clinical context.
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
Authors: Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell, Florence Dalenc, Javier Cortes, Henry L. Gomez Moreno, Xichun Hu, Komal Jhaveri, Petr Krivorotko, Sibylle Loibl, Serafin Morales Murillo, Meena Okera, Yeon Hee Park, Joohyuk Sohn, Masakazu Toi, Eriko Tokunaga, Samih Yousef, Lyudmila Zhukova, Elza C. de Bruin, Lynda Grinsted, Gaia Schiavon, Andrew Foxley, Hope S. Rugo
Journal: New England Journal of Medicine (2023)

AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy, in patients with hormone receptor-positive advanced breast cancer are limited.
Variant <i>STAT4</i> and Response to Ruxolitinib in an Autoinflammatory Syndrome
Authors: Hratch Baghdassarian, Sarah A. Blackstone, Owen S. Clay, Rachael Philips, Brynja Matthiasardottir, Michele Nehrebecky, Vivian K. Hua, Rachael McVicar, Yang Liu, Suzanne M. Tucker, Davide Randazzo, Natalie Deuitch, Sofia Rosenzweig, Adam Mark, Roman Sasik, Kathleen M. Fisch, Pallavi Pimpale Chavan, Elif Eren, Norman R. Watts, Chi A. Ma, Massimo Gadina, Daniella M. Schwartz, Anwesha Sanyal, Giffin Werner, David R. Murdock, Nobuyuki Horita, Shimul Chowdhury, David Dimmock, Kristen Jepsen, Elaine F. Remmers, Raphaela Goldbach-Mansky, William A. Gahl, John J. O’Shea, Joshua D. Milner, Nathan E. Lewis, Johanna Chang, Daniel L. Kastner, Kathryn Torok, Hirotsugu Oda, Christopher D. Putnam, Lori Broderick
Journal: New England Journal of Medicine (2023)

Disabling pansclerotic morphea (DPM) is a rare systemic inflammatory disorder, characterized by poor wound healing, fibrosis, cytopenias, hypogammaglobulinemia, and squamous-cell carcinoma. The cause is unknown, and mortality is high.We evaluated four patients from three unrelated families with an autosomal dominant pattern of inheritance of DPM. Genomic sequencing independently identified three heterozygous variants in a specific region of the gene that encodes signal transducer and activator of transcription 4 (STAT4). Primary skin fibroblast and cell-line assays were used to define the functional nature of the genetic defect. We also assayed gene expression using single-cell RNA sequencing of peripheral-blood mononuclear cells to identify inflammatory pathways that may be affected in DPM and that may respond to therapy.Genome sequencing revealed three novel heterozygous missense gain-of-function variants in STAT4. In vitro, primary skin fibroblasts showed enhanced interleukin-6 secretion, with impaired wound healing, contraction of the collagen matrix, and matrix secretion. Inhibition of Janus kinase (JAK)-STAT signaling with ruxolitinib led to improvement in the hyperinflammatory fibroblast phenotype in vitro and resolution of inflammatory markers and clinical symptoms in treated patients, without adverse effects. Single-cell RNA sequencing revealed expression patterns consistent with an immunodysregulatory phenotype that were appropriately modified through JAK inhibition.Gain-of-function variants in STAT4 caused DPM in the families that we studied. The JAK inhibitor ruxolitinib attenuated the dermatologic and inflammatory phenotype in vitro and in the affected family members. (Funded by the American Academy of Allergy, Asthma, and Immunology Foundation and others.).
A Wrong Turn
Authors: Michael S. Bohnen, Brahmajee K. Nallamothu, Robert Zilinyi, Sanjay Saint, Emily D. Slater
Journal: New England Journal of Medicine (2023)

A 21-year-old woman (gravida 1, para 1) with sickle cell trait presented to the hospital 5 days after delivery with abdominal pain and shortness of breath. She had been well before pregnancy.